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Highlights 
Age-dependent impairment in hippocampal gamma activity in a mouse model of alpha-
synucleinopathy. 
 
Hippocampal slices from mice over-expressing alpha-synuclein show greater sensitivity of 
gamma oscillations to inhibition of mitochondrial function. 
 
Age-dependent impairment in mitochondrial function in a mouse model of alpha-
synucleinopathy. 
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Abbreviations 
 
a-syn  alpha-synuclein 
 
ACSF  artificial cerebrospinal fluid 
 
AD  Alzheimer’s disease 
 
ANOVA analysis of variance 
 
CA1/CA3 cornu amonis 1/3 
 
COX  cytochrome c oxidase 
 
DG  dentate gyrus 
 
DLB  dementia with Lewy bodies 
 
DAB  3,3’-diaminobenzidine  
 
EEG  electroencephalogram 
 
EPSCs excitatory post-synaptic potentials 
 
Hz  Hertz 
 
IQR  interquartile range 
 
KCN  potassium cyanide 
 
LTP  long-term potentiation 
 
mtDNA mitochondrial DNA 
 
NBT  nitroblue tetrazolium  
 
NMDA  N-methyl-D-aspartate 
 
PBS  phosphate buffered saline 
 
PD  Parkinson’s disease 
 
PDD  Parkinson’s disease dementia 
 
PMS  phenazine methosulfate  
 
PV  parvalbumin 
 
RGB  Red, green, blue 
 
r.m.p.  resting membrane potential 
 
SDH  succinate dehydrogenase 
 
s.e.m.  standard error of the mean 
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Abstract  
 
Intracellular accumulation of alpha-synuclein (a-syn) is a key pathological process 
evident in Lewy body dementias (LBD), including Parkinson’s disease dementia (PDD) and 
dementia with Lewy bodies (DLB).  LBD results in marked cognitive impairments and changes 
in cortical networks.  To assess the impact of abnormal a-syn expression on cortical network 
oscillations relevant to cognitive function, we studied changes in fast beta/gamma network 
oscillations in the hippocampus in a mouse line that over-expresses human mutant a-syn 
(A30P). We found an age-dependent reduction in the power of the gamma (20-80 Hz) 
frequency oscillations in slices taken from mice aged 9-16 months (9+), that was not present 
in either young 2-6 months old (2+) A30P mice, or in control mice at either age.  The 
mitochondrial blockers potassium cyanide and rotenone both reduced network oscillations in 
a concentration-dependent manner in aged A30P mice and aged control mice but slices from 
A30P mice showed a greater reduction in the oscillations. Histochemical analysis showed an 
age-dependent reduction in cytochrome c oxidase (COX) activity, suggesting a mitochondrial 
dysfunction in the 9+A30P group. A deficit in COX IV expression was confirmed by 
immunohistochemistry. Overall, our data demonstrate an age-dependent impairment in 
mitochondrial function and gamma frequency activity associated with the abnormal expression 
of a-syn. These findings provide mechanistic insights into the consequences of over-
expression of a-syn which might contribute to cognitive decline. 
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Introduction 
 
 
Abnormal intraneuronal deposition of the synaptic protein alpha-synuclein (a-syn) 
occurs in several neurodegenerative diseases, collectively referred to as the 
synucleinopathies, which include conditions such as Parkinson’s disease (PD), Parkinson’s 
disease dementia (PDD), dementia with Lewy bodies (DLB), and a subgroup of patients with 
Alzheimer’s disease (AD).  a-syn is a small, 140 amino-acid, soluble protein enriched in the 
presynaptic terminal of neurons where it plays a role in vesicular trafficking, neurotransmitter 
release and synaptic maintenance (Cabin et al., 2002; Nemani et al., 2010; Scott et al., 2010).  
Excess misfolded a-syn forms deposits called Lewy bodies, the pathological hallmark of the 
synucleinopathies, which are present throughout the brain including within the hippocampus 
and neocortex (Spillantini et al., 1998; Lassen et al., 2016). 
 
Cognitive dysfunction is a key feature of both PD dementia (PDD) and DLB, which 
together, are the second most common cause of dementia in the elderly after AD. Both PDD 
and DLB are associated with progressive cognitive impairment including memory loss, 
Parkinsonism, attention deficits and complex visual hallucinations (McKeith et al., 2005).  The 
link between abnormal a-syn expression and cognitive impairment is still unclear, but changes 
in network oscillations may underlie many of the cognitive deficits seen in neurodegenerative 
diseases (Nimmrich et al., 2015).  Both AD and DLB patients have a general slowing of the 
electroencephalogram (EEG) activity, particularly from alpha- (8-12 Hz) frequency oscillations 
to slower theta- (4-8 Hz), and delta- (1-4 Hz) oscillations (Bonnani et al., 2008; Morris et al., 
2015; Bonnani et al., 2016).  The majority of the clinical EEG studies in patients have focused 
on lower frequency oscillations in the theta 4-8 Hz and alpha 8-12 Hz bands (e.g. Bonnani et 
al., 2016).  However, fast network oscillations in the beta (20-30 Hz) and gamma (30-80 Hz) 
frequency ranges are also important for cognitive tasks including attention (Clayton et al., 
2015), and memory functions (Watrous et al., 2015; Zheng et al., 2016).  Several studies have 
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reported impaired gamma activity in patients with AD (Herrmann and Demiralp 2005; Basar 
et al., 2016). 
 
Missense mutations, including (A30P) and (A53T), in the human a-syn (SNCA) gene 
have been identified that are linked to early onset familial Parkinson’s disease 
(Polymeropoulos et al., 1997; Kruger et al., 1998).  Several transgenic mouse lines are 
available that over-express either human or mutant a-syn (Kahle et al., 2008; Hatami and 
Chesselet 2015). To assess the impact of abnormal a-syn on cortical network oscillations we 
have used the A30P mouse line that over-expresses human mutant a-syn under the control 
of the CNS promoter Thy-1 (Khale et al., 2000; Neumann et al., 2002).  Previous studies have 
confirmed widespread expression of human mutant a-syn throughout the mouse brain, 
including the hippocampus and neocortex, with cognitive deficits evident at ~12 months of age 
and motor deficits from ~14 months (Kahle et al., 2000; Freishel et al., 2007; Schell et al., 
2009).  One recent study, using an alternative A53T a-syn transgenic mouse line, reported a 
general slowing of the EEG in the theta and alpha bands (Morris et al., 2015), consistent with 
patient data, but the impact of excess a-syn expression on the generation of beta and gamma 
frequency network oscillations is unknown. 
 
Mitochondrial dysfunction is also a key feature of many neurodegenerative diseases 
such as PD and AD (Schon and Przedborski 2011; Spano et al., 2015). Previous studies have 
shown that acute blockade of complex I of mitochondria in slices from normal animals impairs 
the generation of fast network oscillations (Kann et al., 2011; Whittaker et al., 2011).  Excess 
a-syn can translocate to the mitochondrial inner membranes and inhibit function (Nakamura 
et al., 2011), but whether there is a link between excess a-syn, impaired mitochondrial 
function, and network oscillations remains to be determined. 
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In this study we wanted to determine whether a-syn over-expression was associated 
with changes in gamma network oscillations and mitochondrial function. We recorded 
hippocampal gamma frequency activity ex vivo in A30P mice aged between 2 and 16 months 
and compared results with age-matched control C57BL6 mice.  We found significant 
impairments in the power of the gamma frequency activity ex vivo in A30P mice aged >9+ 
months, but not at 2-6 months of age, or in age-matched control mice.  Application of the 
known inhibitors of mitochondrial function (KCN and rotenone) reduced the power of network 
oscillations in older C57BL6 mice and A30P mice but there was a trend for a greater reduction 
in the A30P mice. The deficits in network oscillations were associated with a reduced 
mitochondrial function as indicated by changes in COX/SDH activity in slices only in the older 
9+A30P mice. Our data suggest that excess human mutant a-syn expression in mice causes 
abnormal hippocampal gamma frequency oscillations and impaired mitochondrial function that 
could contribute to cognitive decline.  
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Methods 
Transgenic mice 
The A30P mice (male and female) were bred in house from breeding pairs supplied by 
Dr. P Kahle, University of Tubingen.  Transgenic mice of C57BL6 background expressed 
human mutant A30P a-syn under the control of the CNS specific promoter Thy-1 (Kahle et al., 
2000; Neumann et al., 2002).  The transgenic A30P a-syn were maintained as a homozygous 
colony and aged (2-16 months) in the animal facility.  Control mice (male and female) were 
age-matched C57BL6 supplied from Charles River and also aged in house.  Mice were 
genotyped after transport and breeding to ensure homozygous expression of A30P a-syn in 
the mouse colony.  Animals were housed according to ARRIVE guidelines and were 
maintained on a 12-hour dark/light cycle with lights on at 7.00 am. For most analyses A30P 
mice were divided into two age groups referred to as 2+A30P (2-6 months) and 9+ A30P (9-
16 months) but see Results.  
 
Slice preparation and solutions 
 
All mice were anaesthetised with inhaled isoflurane prior to intramuscular injection of 
ketamine (³ 100 mg kg-1) and xylazine (³ 10 mg kg-1) as described previously (Driver et al., 
2007).  When all response to noxious stimuli, such as pedal withdrawal reflex, had terminated 
the animals were intracardially perfused with ~25 mls of modified artificial cerebrospinal fluid 
(ACSF) that was composed of (mM) 252 sucrose, 3.0 KCl, 1.25 NaH2PO4, 24 NaHCO3, 2.0 
MgSO4, 2.0 CaCl2 and 10 glucose.  This procedure was in accordance with the UK Animals 
(Scientific Procedures) Act 1986 and European Union directive 2010/63EU.  Following brain 
removal, 450 µm thick horizontal slices were cut using a Leica VT1000S vibratome.  Slices 
were then trimmed and transferred to a holding chamber at room temperature for 
approximately 1 hour before being placed in the recording chamber where they were 
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maintained at 32-34°C at the interface between normal ACSF (where sucrose was replaced 
with 126 mM NaCl) and humidified 95% O2/5% CO2.  
 
Drugs: 
Carbachol (10 μM); nitroblue tetrazolium (NBT), phenazine methosulfate (PMS); phosphate 
buffered saline (PBS); potassium cyanide (KCN 50-100 μM); rotenone (250-1000 nM); 
(Sigma-Aldrich, Gillingham, Dorset, UK); HistoClear (Fischer Scientific Ltd., Leicester, UK). 
Rotenone was dissolved in DMSO and stored at -20 °C. 
 
 
Recording and data acquisition 
Extracellular recording electrodes were filled with normal ACSF (resistance 2-5 MW). 
Gamma frequency oscillations were evoked using the cholinergic agonist carbachol (10 µM) 
and field traces were recorded from the border between stratum radiatum and stratum 
lacunosum moleculare in CA3. Data were recorded with an Axoclamp-2B amplifier (Axon 
Instruments Inc., Union City, CA, USA). Extracellular data were filtered at 0.001-0.4 kHz and 
intracellular signals were low pass filtered at 2 kHz using Bessel filters. Mains noise was 
subtracted from the signal with a Humbug (Digitimer, Welwyn Garden City, Herts, UK). Data 
were redigitised at 10 kHz using an ITC-16 interface (Digitimer, Welwyn Garden City, UK). 
Data were recorded and analysed using Axograph 4.6 software (Axon Instruments Inc., Union 
City, CA, USA). Further offline analysis was performed using MATLAB (Mathworks, Natick, 
USA). 
 
Data analysis 
Power spectra were generated using Axograph by Fourier analysis of 60 sec epochs 
of recorded activity to give the peak frequency of the oscillations. Gamma frequency 
oscillations in the mouse have previously been shown to have a slower frequency compared 
to rat ~20-35 Hz (Driver et al., 2007), therefore, a value for area power was determined as the 
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area under the peak in the power spectra between 15-80 Hz. Control oscillations were 
considered “stable” when area power measurements were within ± 10-15% for three 
consecutive recordings at 10-15 min intervals. Rhythmicity was measured from the amplitude 
of the first side peak of the auto-correlations performed over 1 sec traces. The rhythmicity 
index (RI) was on a scale of 0-1.  As multiple slices can be obtained from each animal, in all 
the data reported below two n values N/n represent animal/slice respectively.  
 
a-synuclein and COX IV immunohistochemistry 
Upon termination of electrophysiological recordings, slices were immediately fixed in 
4% buffered paraformaldehyde solution and stored in phosphate buffered saline (PBS) at 4 
°C. Following cryoprotection in 30% sucrose in PBS slices were resectioned at 40 µm with a 
freezing microtome and immunoperoxidase- stained free-floating for either human a-syn using 
anti-human a-syn (Abcam, Cambridge, UK) 1:5000 dilution, or COX IV antibody (Abcam, 
Cambridge, UK) 1:100 dilution using standard histological procedures (secondary reagents 
supplied by Vector Laboratories, Peterborough, UK). Sections were photographed using an 
Axiovision camera and software and Olympus BX-50 microscope. 
 
COX/SDH activity 
Mice were anaesthetised with inhaled isoflurane before an intramuscular injection of 
ketamine and xylazine. Once eye blink and pedal withdrawal reflexes ceased, the brain was 
removed and snap frozen using isopentane immersed in liquid nitrogen. Brains were then 
stored in a -80°C freezer prior to cryosectioning. Snap frozen whole brains were sectioned at 
10 µm using a cryostat at -20°C and collected on to slides. Three sections were collected per 
slide, with each containing at least one hippocampus. All slides were stored at -80°C until 
ready to use. Slides were removed from the freezer and left to dry at room temperature for 1 
hour before use. Wherever possible individual slides were processed in large batches to 
maintain consistency and avoid day-to-day variability in staining. The first section of every 
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slide was used as a control to ensure consistency of COX and SDH media. Half of the control 
slices received COX incubation media only, and the other half received SDH incubation media 
only. All other sections received both COX and SDH media. The COX incubation media was 
prepared by adding 100 µM cytochrome c to 5 mM 3,3’-diaminobenzidine (DAB) and vortexing 
with a few crystals of catalase. COX media (50 µL) was applied to each section, and all slides 
were incubated for 40 minutes at 37°C. COX media was then removed and 2 x five minute 
washes with 0.1 M phosphate buffered saline (PBS) were performed. After the final wash, 
excess PBS was removed from the slides. 
 
The SDH incubation media was prepared by vortexing together 1.5 mM nitroblue 
tetrazolium (NBT), 130 mM sodium succinate, 0.2 mM phenazine methosulfate (PMS), and 
1.0 mM sodium azide. Care was taken to protect the sensitive PMS (and resultant final media) 
from light. SDH media (50 µL) was applied to each section, and all sections were incubated 
for 40 minutes at 37°C. SDH media was then removed and 2 x five minute washes with 0.1M 
PBS were carried out. Slides were dehydrated through an ethanol gradient (70%, 95%, 100%, 
100%) with 5 minutes in each ethanol solution and 10 minutes in the final 100% ethanol 
solution. Slides were then transferred to two consecutive pots of HistoClear for five minutes 
of clearing in each and then mounted with DPX.  
 
Quantification of COX/SDH staining and anti-COX IV immunohistochemical staining 
Using an Olympus BX51 stereology microscope with an Olympus U-TV1X-2 T2 
camera, colour images of COX/SDH staining were taken at x10 magnification of the CA3 
region of the hippocampus. All slides were assigned a random numerical value to blind the 
imaging and quantification processes.  In the presence of normal COX activity, the brown DAB 
precipitate which forms inhibits the formation of the blue NBT precipitate with SDH activity 
(Trifunovic et al., 2004). Therefore, normal COX activity would appear as brown, while a 
complete absence of COX activity would appear as blue.  Using ImageJ’s histogram tool 
((http://rsb.info.nih.gov/ij/), a freehand selected area of the CA3 pyramidal layer could be 
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analysed for its mean RGB (red, green, blue) constitution. All values were noted, but the mean 
blue value (no blue = 0, maximum blue = 255) was compared as a measure of mitochondrial 
dysfunction. Values obtained from sections were compared to control sections stained for 
either COX (brown) or SDH (blue) alone.  Multiple sections (2-7) per mouse were averaged to 
give an average per animal, and then animals were compared on average for the young 
2+A30P and older 9+A30P groups using an unpaired t test. 
 
Low power black and white Images of COX IV immunoperoxidase staining were 
analysed using ImageJ. The stratum pyramidale of the CA3 region was outlined and the area 
and mean optical density (white = 0, black = 255) of the immunostaining within this region of 
interest was measured and normalized against background staining by subtracting the mean 
optical density of a nearby area of white matter. Six sections were analysed for each animal, 
and for each section the total optical density was calculated by multiplying area by the mean 
optical density.  The mean optical density for each animal was calculated by dividing total 
density by total area from the six sections analysed. Results from 2+A30P (N=3) mice were 
compared with 9+A30-P (N=3) mice.  
 
Statistical Analysis 
Data were statistically analysed using Sigmaplot (v12.5) to determine whether it 
corresponded to a normal (Gaussian) distribution. Normally distributed data were plotted as 
mean ± s.e.m and compared using a Student’s t-test.  Due to the normal variability, especially 
in gamma frequency area power, all electrophysiological data were analysed using non-
parametric statistics on the raw data and described as median and interquartile ranges (IQR)  
or percentage change. When comparing two different groups we used a Mann Whitney rank 
sum text. A Wilcoxon signed rank test were used for comparing before and after conditions in 
the same sample. Repeated measures on the same sample were analysed using a 
Friedman’s repeated measures ANOVA.  Multiple groups were compared using Kruskal-Wallis 
one-way ANOVA on ranks. If the p value for the ANOVA tests showed a significant difference 
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a Dunn’s or Tukey’s (all pairwise multiple comparison) test was performed to determine which 
parameters were significantly different. p values are reported as significant <0.05 and <0.001.  
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Results 
 
Alpha-syn expression in A30P mice 
 
Immunohistochemical analysis using the human-specific a-syn antibody (see 
Methods) in slices from the 2+A30P group, confirmed widespread expression of human a-syn 
throughout the brain including stratum pyramidale in the hippocampus (Fig. 1A).  There was 
no staining for human a-syn in the hippocampal pyramidal cell layer in age-matched control 
C57BL6 mice (Fig. B). A similar staining pattern was observed for both 9+A30P and the 9+C57 
mice (data not shown). 
 
  
Over-expression of a-syn results in an age-dependent decline in gamma frequency activity. 
 
 
Cognitive impairments in the A30P mice have been reported at 12 months of age 
(Kahle et al., 2000; Freichel et al., 2007), therefore, to assess network oscillations we initially 
divided A30P mice into four age groups referred to as 2+ (2-6 months n = 21 mice/45 slices); 
9-11 months n = 7 mice/18 slices, 12-13 months n = 7 mice/18 slices, and 14+ (14-16 months, 
n = 3 mice/8 slices). Gamma frequency oscillations can be readily evoked in the CA3 region 
of the hippocampus following activation of cholinergic receptors with carbachol (Fisahn et al., 
1998; Mann et al., 2005). After application of carbachol (10 µM) the area power of the gamma 
frequency oscillations increased gradually for 2-4 hours as previously reported (Lu et al., 2012; 
Haggerty et al., 2013), and measurements were made once oscillations had stabilised (see 
Methods). 
 
Our data demonstrated an age-dependent decrease in the area power of the gamma 
frequency oscillations in the A30P mice (Fig. 2A-E, Table 1).  Area power of the gamma activity 
was significantly different between the 2+A30P, 9-11A30P, 12-13A30P and 14+A30P groups 
(Kruskal-Wallis one-way ANOVA on ranks, p<0.001).  A pairwise multiple comparisons test 
(Dunn’s method) showed that slices from the 2+A30P group had significantly larger 
oscillations than the 9-11A30P, 12-13A30P, 14+A30P groups, and versus all 9+A30P data 
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combined.  However, there was no significant difference between any of the older age groups 
(Fig. 2E). Table 1 shows the median and IQR values for area power in each age group.   
 
In contrast, the frequency of the gamma oscillation was not significantly different (Fig. 
1F) between any of the different age groups of A30P mice (Kruskal-Wallis one-way ANOVA 
on ranks, p>0.001; Table 1).  In addition, there was a significant difference in RI values (Fig. 
1G, Table 1) overall (Kruskal-Wallis one-way ANOVA on ranks, p>0.001; Table 1); however, 
a pairwise multiple comparisons test (Dunn’s method) did not reveal any significant differences 
between specific groups.  As slices from the 9-11A30P, 12-13A30P or 14+A30P and all 
9+A30P combined groups all showed reduced gamma frequency area power compared to the 
2+A30P group, these older age groups were combined into the so-called 9+A30P group for 
all subsequent analysis (Table 1).   
 
No gender differences in the power of network oscillations in the A30P mice 
Both the 2+ and 9+A30P groups contained data obtained from male and female mice. 
Therefore, we also assessed these groups separately, but found no significant difference in 
the stable area power between slices taken from male and female mice (Fig. 3A).  Stable area 
gamma frequency power in 2+A30P male mice was 2066 (IQR 1115 - 4966; n = 5 mice/11 
slices) μV2 compared with 3325 (IQR 2252 - 6216; n = 16 mice/34 slices) μV2 in the female 
2+A30P mice (Kruskal-Wallis one-way ANOVA on ranks p>0.05).  In the 9+A30P group there 
was also no significant difference between slices taken from male and female mice. Stable 
area gamma frequency power in 9+A30P male group was 306 (IQR 124 - 1355; n = 11 mice/30 
slices) μV2 compared with 1484 (IQR 265 - 2254; n = 5 mice/14 slices) μV2 in the female 
2+A30P group (Kruskal-Wallis one-way ANOVA on ranks p>0.05).  Importantly, slices taken 
from male and female mice both showed an age-dependent reductions in the area power of 
the gamma frequency activity between 2+A30P and 9+A30P age groups (p<0.05, Kruskal-
Wallis one-way ANOVA on ranks, Fig. 3A). 
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The frequency of the gamma oscillation (Fig. 3B) for the 2+A30P male mice was 25.6 
(IQR 23.9 - 27.0; n = 5 mice/11 slices) Hz compared with 25.1 (IQR 23.4 - 26.8; n = 16 mice/34 
slices) Hz in the female 2+A30P mice (p>0.05). In the 9+A30P group there was a median 
frequency of 23.6 (IQR 21.6 - 25.7; n = 11 mice/30 slices) Hz in male mice compared with 
26.7 (IQR 23.7 - 27.7; n = 5 mice/14 slices) Hz in the female 2+A30P group. There were no 
significant differences between the groups (Kruskal-Wallis one-way ANOVA on ranks, 
p>0.05).  RI values were also assessed separately for slices from male and female mice (Fig. 
3C).  For the 2+A30P male mice RI was 0.59 (IQR 0.16 -0.75) compared to 0.67 (IQR 0.48 - 
0.74) for female.  In the 9+A30P group RI in the male group was 0.29 (IQR 0.13 - 0.59) 
compared to 0.48 (IQR 0.24 - 0.75) in the female group.  Again, as above for RI values, there 
was a significant difference overall (Kruskal-Wallis one-way ANOVA on ranks, p<0.05) but a 
multiple comparison procedure did not reveal specific group differences. 
 
No age-dependent change in stable gamma frequency activity in control C57 mice 
Previous in vitro studies have shown an age-dependent decrease in hippocampal 
gamma oscillations in control mice, but only after approximately >16 months (Vreugdenhil et 
al., 2005; Driver et al., 2007).  In order to confirm the age-dependent deficit observed in the 
A30P mice was a consequence of human mutant a-syn expression, and not due to normal 
ageing, we compared a similar age-matched group of control C57BL6 (male only) mice divided 
into similar 2+ and 9+ age groups.  
 
In contrast to the data reported above for the A30P mice, we found no age-dependent 
changes in gamma frequency activity between 2+ and 9+C57 mice (Fig. 4A-G).  Stable 
gamma frequency area power in slices taken from 2+C57 mice was 4779 (IQR 1876 - 9309; 
n = 6 mice/19 slices) μV2 compared with 2190 (IQR 415 - 7928; n = 6 mice/15 slices) μV2 in 
slices taken from 9+C57 mice (Mann Whitney rank sum test p>0.05).  There was also no 
difference in the frequency of the gamma oscillations between 2+C57 and 9+C57 control mice 
(Fig. 5F). The median frequencies in 2+C57 and 9+C57 were 23.3 (IQR 22 - 24.7; n = 6 
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mice/19 slices) Hz and 25.2 (IQR 22.3 – 26.4; n = 6 mice/15 slices) Hz, respectively (Mann 
Whitney rank sum test p>0.05). We also assessed possible changes in rhythmicity between 
the 2+ and 9+C57 mice but there was no significant difference in RI values between the two 
groups. Median RI in the 2+C57 mice was 0.57 (IQR 0.5 – 0.65) and 0.49 (IQR 0.2 – 0.6) in 
the 9+C57 mice (Mann Whitney rank sum test p>0.05). 
 
A one way-ANOVA comparing all four groups (2+A20P, 9+A30P, 2+C57 and 9+C57) 
showed a significance difference (p<0.001; Kruskal-Wallis one-way ANOVA on ranks).  Post-
hoc analysis confirmed that the gamma frequency area power was significantly smaller only 
in the 9+A30P (Dunn’s pairwise multiple comparison). The above data, therefore, demonstrate 
an age-dependent reduction in gamma frequency power in the older A30P mice that occurs 
prior to any normal age-related decline in gamma activity in control mice. 
 
Effects of mitochondrial inhibitors on network gamma frequency oscillations 
Previous studies have shown that hippocampal gamma frequency oscillations evoked 
in vitro are sensitive to blockade of mitochondrial complex I and complex IV, with rotenone 
and KCN respectively (Kann et al., 2011; Whittaker et al., 2011). If the impaired gamma 
frequency activity observed in the 9+A30P mice reflected an age-dependent reduction in 
mitochondrial function, we predicted we might observe a greater sensitivity of the oscillatory 
activity to inhibition of mitochondrial function in slices from the older A30P mice. Thus we 
compared the concentration-dependent effects of potassium cyanide (KCN 25, 50 and 100 
μM), and rotenone (250, 500, and 1000 nM), on stable carbachol-evoked gamma frequency 
oscillations from older C57 and A30P mice (Fig. 5).  
 
Once oscillations were stable KCN was bath applied incrementally every 30 mins with 
readings taken at 10 min intervals (Fig. 5A-B). There was a rapid reduction in gamma 
oscillatory power within 10 mins in slices from both 9+C57 (n = 4 mice/10 slices) and 9+A30P 
C57 (n = 3 mice/6 slices) mice.  Compared to control stable values statistically significant 
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reductions were evident at 50 μM and 100 μM in both 9+C57 and 9+A30P groups (Freidman’s 
repeated measures ANOVA on ranks followed by Tukey post-hoc multiple comparisons test 
p<0.05).  At the final concentration of KCN tested the power of the gamma activity was reduced 
by -77 ± 7.6% in 9+C57 group and -82.6 ± 8.3% in the 9A30P group.  
 
In a further set of experiments, we also tested rotenone and this appeared less 
effective than KCN.  In the control 9+C57 group (n = 7 mice/21 slices) there was a clear trend 
towards a concentration dependent reduction in gamma power (Fig. 5C) but this was not 
statistically different at any point when compared to stable control levels (Freidman’s repeated 
measures ANOVA on ranks followed by Tukey post-hoc multiple comparisons test p>0.05). 
However, in the 9+A30P group (n = 6 mice/18 slices) at the higher concentrations rotenone 
did cause a statistically significant decrease compared to stable gamma power (Freidman’s 
repeated measures ANOVA on ranks followed by Tukey post-hoc multiple comparisons test 
p<0.05).  At the final concentration of rotenone tested the power of the gamma activity was 
reduced by -29.6 ± 9.8% in 9+C57 group and -41.9 ± 8.8% in the 9A30P group. The greater 
decrease in gamma frequency oscillations with rotenone suggests slices from the 9+A30P 
mice are more sensitive to this mitochondrial inhibitor. 
 
Age-dependent mitochondrial dysfunction in the A30P mice 
The above data suggested that the age-dependent impairment in the power of the 
gamma frequency oscillation seen in older A30P mice might reflect a mitochondrial 
dysfunction in these animals. COX/SDH histochemistry (see Methods) was performed on 
sections from 2+A30P (N = 5 mice) and 9+A30P (N = 5 mice) groups.  While we did not detect 
COX deficiency within individual neurons, a general reduction in COX reactivity was seen 
across the hippocampus. In order to ascertain if there was any difference in the activity of 
mitochondria in these sections we measured the changes in RGB balance in the CA3 stratum 
pyramidale, with increased blueness indicating a loss of COX activity (see Methods).  The 
 21 
mean blue values for COX alone control was 39.5 ± 2.8 compared to 120.4 ± 4.1 for SDH 
alone control (Fig. 6A-B) and these control values were highly significantly different (p <0.001).  
Overall in the 2+A30P the mean blue level was 45.17 ± 2.9 compared to 52.59 ± 1.73 in the 
9+A30P group, which was a statistically significant change in COX/SDH histochemistry in the 
CA3 stratum pyramidale (Fig. 6E-F) in the older 9+A30P (Un-paired t-test p<0.05).  The 
increased mean blue level suggested an age-dependent decline in mitochondrial COX activity 
and expression and, therefore, a decrease in mitochondrial function in the 9+A30P group.  Of 
note, there was considerable variability between individual mice in the younger 2+A30P group 
(Fig. 6E). In a further set of experiments immunohistochemistry for COX IV immunoperoxidase 
in the stratum pyramidale of the CA3 region also showed a significant 23.3% reduction in 
optical density in the 9+A30P group compared to slices from 2+A30P mice (136.7 ± 5.0 to 
104.9 ± 5.0, N = 3, p<0.05, Fig. 6I). Combined, these data suggest an age-dependent 
impairment in COX activity and expression indicating a mitochondrial dysfunction was present 
in the older 9+A30P group. 
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Discussion 
 
 
In this study we have demonstrated an age-dependent reduction in hippocampal 
gamma frequency oscillations in slices from older 9+A30P mice, compared with younger 
2+A30P mice, or age-matched control animals. Oscillations in both control C57BL6 mice and 
A30P mice were sensitive to inhibitors of mitochondrial function but a greater reduction in area 
power was seen in the older A30P group. COX/SDH staining and anti-COX IV 
immunohistochemistry revealed a significant age-related decline in mitochondrial function in 
A30P mice.  
 
Although human a-syn expression was clearly evident in young animals (2+A30P), the 
deficits in gamma activity were only seen in the older 9+A30P mice.  One possible explanation 
for the age-dependence of the change is that reductions in gamma frequency oscillations 
might be a consequence of a progressive increase in pathology.  a-syn is expressed in the 
A30P mice from one month of age (Kahle et al., 2000). However, posttranslational 
modifications of a-syn, such as phosphorylation or ubiquitination, are associated with Lewy-
like pathology in both humans and in mouse a-synucleinopathy models (Lim et al., 2011).  In 
the A30P mice an age-dependent increase in Serine-129 phosphorylation has been reported, 
that correlated with the cognitive deficits observed in these animals at 12 months of age 
(Schell et al., 2009).  In this study the deficits in gamma activity were evident at 9-11 months 
of age in the A30P mice, with no significant further changes observed up to 14-16 months of 
age.  This suggests the reductions in gamma frequency activity occur just prior to the onset of 
quantifiable cognitive dysfunction.   
 
It is not yet known how abnormal a-syn expression might affect synaptic transmission, 
and the generation of gamma frequency oscillations in the hippocampus. In human post-
mortem tissue from patients with a confirmed diagnosis of DLB, a-syn aggregates were found 
to localize at the synaptic terminal (Kramer and Schultz-Schaffer 2007). a-syn is known to 
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undergo misfolding and oligomerisation forming dimers, oligomers and fibrils (Ingelsson 
2016). It is now generally accepted that the oligomeric form is the most toxic, rather than the 
larger intracellular inclusions.  These oligomeric structures may also be transmitted in a prion-
like manner through brain structures (Ingelsson 2016), and thus could impair synaptic 
transmission in subtle ways long before major cognitive decline is evident in the A30P mice.  
Gamma oscillations in the hippocampus depend upon reciprocal interactions between 
pyramidal cells and fast-spiking GABAergic interneurons (Whittington et al., 2011) that contain 
the calcium binding protein parvalbumin (PV).  The age-dependent reduction in gamma 
activity observed in the 9+A30P mice could reflect changes in either pyramidal cells, 
interneurons or both and further studies are required to see which cell types are affected or 
might be selectively vulnerable to a-syn toxicity. However, evidence suggests PV interneurons 
are particularly vulnerable to metabolic stress due to the high energy demand of their fast 
firing rates (Kann et. al., 2014). Data from AD transgenic mice have implicated loss of PV 
interneuron function as a key contributor to deficits in network oscillations (Palop and Mucke 
2016).  In addition, reductions in PV-positive interneuron staining have been reported in 
human post-mortem studies in both AD (Brady and Mufson 1997) and DLB (Bernstein et. al. 
2011). Further studies are needed to determine if the deficits in gamma frequency activity 
observed in aged A30P also reflect dysfunction of PV interneurons. 
 
Abnormal a-syn expression in transgenic mice has been associated with both network 
hyperexcitability (Morris et al., 2015) and mitochondrial dysfunction (Chinta et al., 2010; 
Rothman et al., 2014; Martin et al., 2014; Chen et al., 2015).  a-syn is found in the mitochondria 
and recently it was shown that a-syn associated with the mitochondria modulates 
mitochondrial transport and morphology (Pozo Deveto et al., 2017).  In transgenic mice that 
over-express human mutant A53T a-syn both mitochondrial motility (Li et al., 2013) and 
function (Martin et al., 2014) are impaired.  The study by Pozo Deveto et al., (2017) also 
showed, however, that the effects of over-expression of A53T a-syn in human and mouse 
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derived neuronal cultures were significantly greater than those of over-expression of A30P a-
syn. This is in alignment with the observation that the A30P mutation in humans is associated 
with later onset and less severe clinical symptoms in patients than those seen with the A53T 
mutation (Kruger et al., 2001; Puschman et al., 2009). Our data showed a significant age-
dependent impairment of both gamma frequency activity, and mitochondrial function, which 
would be consistent with a slow progression of neurodegenerative changes in the A30P 
transgenic mice. 
 
Our data using the mitochondrial inhibitors KCN and rotenone showed a concentration 
dependent reduction in the power of the gamma frequency activity in both aged wild type C57 
mice and A30P mice. Rotenone blocks mitochondrial complex I while KCN blocks complex IV.  
Previously, high concentrations of both KCN (100 µM) and rotenone (1 µM) have been shown 
to cause a rapid collapse of the gamma oscillations (Kann et al., 2011; Whittaker et al., 2011).  
We had predicted that if A30P mice developed compromised mitochondrial function with age 
then slices taken from the older A30P mice may be more sensitive to lower concentrations of 
the inhibitors.  While we saw no difference between 9+C57 and 9+A30P groups with KCN, the 
results with rotenone did suggest a slightly greater sensitivity of the oscillations in the 9+A30P 
group. 
 
A previous study (Whittaker et al., 2011) showed that KCN (100 µM) had no effect on 
pyramidal cell properties or excitatory post-synaptic potentials (EPSP) onto the pyramidal 
cells, suggesting the changes in oscillations were not mediated by reductions in glutamatergic 
neurotransmission. In contrast, these authors found a reduction in inhibitory post-synaptic 
potential (IPSPs) on the pyramidal cells, while fast-spiking interneurons were depolarized and 
spiking activity in the interneurons was abolished (Whittaker et al., 2011).  This loss of action 
potential firing in fast spiking interneurons, and the subsequent decrease in IPSP amplitude 
could account for the reduction in gamma frequency oscillations observed both in their study 
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and in the current experiments. As outlined above the higher sensitivity of interneurons to 
inhibition of mitochondrial function is consistent with their high metabolic requirements (Kann 
et al., 2016). Rotenone block of complex I can cause either an increase in reactive oxygen 
species (ROS) or ATP depletion. It would be interesting in further studies to assess whether 
interventions that prevent oxidative stress and energy failure have any impact on the impaired 
gamma frequency activity in the older A30P mice. 
 
COX/SDH histochemistry detects alterations in the activity of complex IV and II 
respectively, and we found a significant deficit in COX activity and presumably expression in 
the 9+A30P group, although SDH expression in complex II was retained. An age-dependent 
deficit in COX IV expression was confirmed by immunohistochemistry in the 9+A30P group. 
This result is suggestive of mitochondrial dysfunction, which may be caused by mutations in 
key mitochondrial genes either within mitochondrial DNA (mtDNA) or the nucleus. In ageing 
human neurons, a reduction in COX activity is predominantly associated with deletions within 
mtDNA, which is vulnerable to oxidative damage, whereas the preservation of SDH activity in 
these situations is because it is entirely nuclear encoded, meaning that its activity is not 
affected by mutations in mtDNA (Bender et al., 2006; Kraytsberg et al., 2006; Krishnan et al., 
2012). The variability in COX staining seen between different mice in the 2+A30P group may 
also indicate early changes, which while not significant as a group, suggest changes in 
mitochondrial function may already be starting to occur in some animals. Although from the 
current study we cannot ascertain whether the mitochondrial dysfunction is cell type specific, 
impairments in pyramidal cells and/or fast-spiking interneurons could result in the reduction in 
gamma frequency activity observed in the older 9+A30P mice. 
 
Conclusions 
Several studies have shown that a-syn oligomers impair hippocampal LTP, which is 
thought to represent the cellular mechanism of learning and memory. However, to our 
knowledge, this is the first study to report deficits in cognitively relevant, beta/gamma 
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frequency network oscillations in the hippocampus in mice that express abnormal human 
mutant α-syn.  We have shown a consistent deficit in oscillations in aged mice overexpressing 
a-syn that precedes reported behavioural deficits and correlates temporally with observed 
changes in mitochondrial function.  
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Figure Legends 
 
Figure 1 – Alpha synuclein expression in the hippocampus. 
A) Immunohistochemistry shows strong human a-syn immunostaining in the hippocampus, 
especially in the stratum pyramidale, of 2+A30P mice. (B) 2+C57 mice do not express human 
a-syn, although some non-specific staining is observed in erythrocytes and around the section 
edges.   Hippocampal regions Cornu Ammonis 1 (CA1), Cornu Ammonis 3 (CA3) and dentate 
gyrus (DG) are indicated. Scale bar = 100 µM.  
 
Figure 2 - Age-dependent reduction in gamma frequency activity in A30P mice. 
A) Representative 1 sec extracellular field trace in 2+A30P (blue) following 30 min bath 
application of carbachol (10 µM) and the corresponding power spectra. Inset shows auto-
correlation. (B) Representative 1 sec extracellular field trace when stable gamma activity was 
reached and corresponding power spectra. Inset shows auto-correlation. C) Representative 1 
sec extracellular field trace (maroon) in 9+A30P following 30 min bath application of carbachol 
(10 µM) and corresponding power spectra. Inset shows auto-correlation. (D) Representative 
1 sec extracellular field trace when stable gamma activity was reached and corresponding 
power spectra. Inset shows auto-correlation. Note different scales on power spectra for 2+ 
and 9+A30P mice.  E)  Boxplot shows the median (whiskers max to min) area power of the 
gamma frequency activity in all age groups (1 outlier removed from plot).  Asterix (*) indicates 
power in the 2+A30P group was significantly different from all other groups (p<0.05; Kruskal-
Wallis One-way ANOVA on ranks) and post-hoc all pairwise multiple comparison (Dunn’s 
method). F) Boxplot shows the median (whiskers max to min) frequency of the gamma 
frequency activity in all age groups.  There was no significant difference between any group 
(p>0.05; Kruskal-Wallis One-way ANOVA on ranks). G) Boxplot shows median (whiskers max 
to min) RI index of the gamma frequency activity in all age groups.  There was a significant 
difference between the groups (p<0.05; Kruskal-Wallis One-way ANOVA on ranks but post 
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hoc all pairwise multiple comparison (Dunn’s method) did not reveal specific group 
differences. Scale bars for auto-correlation 0.5/100 ms. 
 
Figure 3 – Area power and frequency in slices from male versus female A30P mice. 
A) Boxplot shows the median (whiskers max - min) area power of the gamma frequency 
activity for slices from male versus female 2+A30P and 9+A30P mice. Power in the male 
2+A30P group was significantly different from male 9+A30P group (p<0.05; Mann Whitney 
rank sum test). Power in the female 2+A30P group was significantly different from female 
9+A30P group (p<0.05; Mann Whitney rank sum test).  B) Boxplot shows the median (whiskers 
max - min) frequency of the gamma frequency activity for slices from male versus female 
2+A30P and 9+A30P mice.  There was no significant difference in frequency between male 
and female mice in the 2+A30P or 9+A30P groups (p>0.05; Mann Whitney rank sum test).  C) 
Boxplot shows the median (whiskers max - min) RI of the gamma frequency activity for slices 
from male versus female 2+A30P and 9+A30P mice.  There was a significant difference 
between the groups (p<0.05; Kruskal-Wallis One-way ANOVA on ranks but post-hoc all 
pairwise multiple comparison (Dunn’s method) did not reveal specific group differences. 
 
Figure 4 – No age-dependent changes in gamma frequency activity in control C57BL6 
mice. 
A) Representative 1 sec extracellular field trace in 2+C57 (green) following 30 min bath 
application of carbachol (10 µM) and the corresponding power spectra. Inset shows auto-
correlation. (B) Representative 1 sec extracellular field trace when stable gamma activity was 
reached and corresponding power spectra. Inset shows auto-correlation. C) Representative 1 
sec extracellular field trace in 9+C57 (brown) following 30 min bath application of carbachol 
(10 µM) and corresponding power spectra. Inset shows auto-correlation. (D) Representative 
1 sec extracellular field trace when stable gamma activity was reached and corresponding 
power spectra.  Inset shows auto-correlation. E) Boxplot shows the median (whiskers max – 
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min) area power of the gamma frequency activity in both age groups. Power in the 2+C57 
group was not significantly different from the 9+C57 group (p>0.05; Mann Whitney rank sum 
test). F) Boxplot shows the median (whiskers max - min) frequency of the gamma frequency 
activity in both age groups.  There was no significant difference between any group (p>0.05; 
Mann Whitney rank sum test). G) Boxplot shows the median (whiskers max - min) RI of the 
gamma frequency activity in both age groups.  There was no significant difference between 
any group (p>0.05; Mann Whitney rank sum test). Scale bars for auto-correlation 0.5/100 ms. 
 
Figure 5 – Effects of mitochondrial inhibitors on network oscillations in the 
hippocampus. 
A) Histogram shows percentage change in area power at 10, 20 and 30 mins after application 
at each concentration of KCN (25 µM, 50 µM and 100 µM) in the 9+C57 group. B) Histogram 
shows percentage change in area power at 10, 20 and 30 mins after application at each 
concentration of KCN (25 µM, 50 µM and 100 µM) in the 9+A30P group. C) Histogram shows 
percentage change in area power at 10, 20 and 30 mins after application at each concentration 
of rotenone (250 nM, 500 nM and 1000 nM) in the 9+C57 group. D) Histogram shows 
percentage change in area power at 10, 20 and 30 mins after application at each concentration 
of rotenone (250 nM, 500 nM and 1000 nM) in the 9+A30P group. * indicates significantly 
different from stable control area power (Freidman’s repeated measures ANOVA on ranks and 
post hoc Tukey test p<0.05). 
 
Figure 6 – Age-dependent reduction in mitochondrial function in A30P mice. 
A) Representative sections from the hippocampal CA3 region showing COX activity and (B) 
SDH activity only in sections from the 2+A30P group. Inset histograms show the individual 
blue stain intensity in the RGB spectra using ImageJ for each section shown. C) 
Representative sections from the hippocampal CA3 region and inset histograms of blue stain 
intensity in the RGB spectra using ImageJ values from 2+A30P animals and (D) 9+A30P 
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where the mean blue intensity level is significantly increased, indicating a reduction in COX 
activity.  Scale bars = 100 µM.  E) Mean blue intensity levels for each mouse in 2+A30P and 
(F) 9+A30P groups. There was significant variability between values for individual mice in the 
2+A30P group. G) Shows examples of anti-COX immunostaining in 2+A30P and (H) 9+A30P 
mice. I) Mean optical density measurements from the CA3 stratum pyramidale revealed a 
significant decrease in immunoreactivity in the 9+A30P group. 
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